| Literature DB >> 30035021 |
Zhenyu Liu1, Yinyan Wang2, Xing Liu2, Yang Du1, Zhenchao Tang3, Kai Wang4, Jingwei Wei1, Di Dong1, Yali Zang1, Jianping Dai4, Tao Jiang5, Jie Tian6.
Abstract
Purpose: To investigate the association between imaging features and low-grade gliomas (LGG) related epilepsy, and to propose a radiomics-based model for the prediction of LGG-associated epilepsy.Entities:
Keywords: Elastic net; Epilepsy; Low grade gliomas; Radiomics; T2WI
Mesh:
Year: 2018 PMID: 30035021 PMCID: PMC6051495 DOI: 10.1016/j.nicl.2018.04.024
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Clinical characteristic of patients in the primary and validation cohorts.
| Characteristics | Primary cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Epilepsy | No epilepsy | Epilepsy | No epilepsy | |||
| Age, y, median (range) | 37(15–64) | 40(17–67) | 0.197 | 42(17–66) | 45(8–72) | 0.249 |
| Sex, M/F | 81/55 | 29/29 | 0.219 | 41/19 | 16/16 | 0.085 |
| MRI characteristics | ||||||
| Tumor size, mean ± SD | 73.5 ± 51.2 | 72.6 ± 58.3 | 0.867 | 71.4 ± 54.5 | 73.2 ± 60.1 | 0.796 |
| Tumor pathology (%) | ||||||
| Oligodendroglioma | 14 | 10 | 0.178 | 7 | 1 | 0.166 |
| IDH-mutant and 1p/19q-codeleted | 10 | 5 | 4 | 1 | ||
| NOS | 4 | 5 | 3 | 0 | ||
| Diffuse Astrocytoma | 43 | 19 | 0.876 | 18 | 14 | 0.187 |
| IDH-mutant | 26 | 10 | 9 | 8 | ||
| IDH-wildtype | 7 | 3 | 3 | 3 | ||
| NOS | 10 | 6 | 6 | 3 | ||
| Oligoastrocytoma | 79 | 29 | 0.299 | 35 | 17 | 0.631 |
| NOS | 79 | 29 | 35 | 17 | ||
| Radiomics score | 0.8236 ± 0.29173 | 0.3540 ± 0.29742 | <0.001 | 0.6715 ± 0.37991 | 0.3734 ± 0.28888 | <0.001 |
NOS, not otherwise specified.
Result of t-test.
Fig. 1Flowchart of the study. With manually segmented tumor, we first extracted 474 quantitative imaging features, including location features, 3-D imaging features, and their interactions from masked presurgical T2-weighted MRIs. The general view of the feature extraction algorithm was shown in the figure. Then, feature selection was applied on the extracted features with E-net and a radiomics signature was constructed with the selected features. Finally, radiomics signature and clinical characteristics were incorporated into a nomogram for individually prediction.
Fig. 2Tumor masking and quantitative location information. Masks of the brain tumors were drawn on each patient's T2-weighted images in native space by two board-certified neuroradiologists. We set up a coordinate system with the anterior commissure (AC) as the origin point. Polar coordinates (r, θ, and Φ) of the centroid of the tumor were identified as location features.
Quantitative image features extracted for prediction.
| Class | Features | Numbers | |
|---|---|---|---|
| Location | First order statistics | Polar coordinate (r, | 7 |
| Shape based features | Energy, Entropy, Kurtosis, Mean, Maximum, Minimum, Median, Range, RMS, Skewness, Variance, Standard deviation, Uniformity | 13 | |
| Textural features | Compactness I, Compactness II, sphericity, spherical disproportion, Surface to volume ratio (SVR), Volume, Surface area | 7 | |
| Wavelet features | Gray level co-occurrence matrix (GLCM)'s: | 25 | |
| 3D “Coiflet 1” wavelet transform on images with 8 decompositions: LLL, LLH, LHL, LHH, HLL, HLH, HHL, HHH; Then re-calculate the first order statistics features and textural features. | 304 | ||
| Interaction features | Statistically significant ( | 119 | |
| Total | 475 | ||
Fig. 3ROC curve of multivariate analysis with location features (A) and 3-D imaging features (B) (the pink lines represent the performance in the primary cohort and the blue lines represent the performance in the validation cohort). (C) Tuning parameter (λ) selection in the E-net used 10-fold cross-validation via minimum criteria. (D) ROC curve of radiomics signature (the pink lines represent the performance in the primary cohort and the blue lines represent the performance in the validation cohort).
Performance of the different features.
| Metrics | AUC | Accuracy | ||
|---|---|---|---|---|
| Primary cohort | Validation cohort | Primary cohort | Validation cohort | |
| Location (95%) | 0.7567 (0.7146 to 0.7962) | 0.6541 (0.6237 to 0.7065) | 70.10% (64.95% to 74.74%) | 66.30% (61.96% to 69.56%) |
| 3-D Imaging features (95%) | 0.7857 (0.7563 to 0.8364) | 0.7612 (0.7072 to 0.7921) | 75.26% (72.16% to 77.32%) | 70.65% (66.30% to 73.91%) |
| Radiomics signature (95%) | 0.8754 (0.8265 to 0.9213) | 0.8162 (0.7318 to 0.9005) | 79.38% (76.22% to 82.22%) | 75.00% (71.74% to 78.26%) |
Abbreviations: AUC, area under ROC curve.
Fig. 5Developed radiomics nomogram. The radiomics nomogram was developed in the primary cohort, with the radiomics signature and clinical characteristics (including sex, age, and histopathology) incorporated. With the nomogram, probability of epilepsy for each patient could be calculated on the basis of logistic regression formula using the total points.
Fig. 6Calibration curve of the radiomics nomogram in the primary cohort.
Fig. 4T2-weighted images with tumor masks for two cases with LGG. Top row: images in a patient who was classified into the epilepsy group with an epilepsy risk score of 1.1066. Bottom row: images in a patient who was classified into the non- epilepsy group with a radiomics score of −0.0970. (Patients with radiomics score >0 would be classified into epilepsy group, while patients with radiomics score <0 would be classified into non-epilepsy group).